Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English | Polski
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antiviral Agents"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 167239

Starter badań:

Podgląd okładki
Tytuł :
Nucleosides and emerging viruses: A new story.
Autorzy :
Roy V; ICOA, University of Orléans, CNRS UMR 7311, Rue de Chartres, 45067 Orléans, France.
Agrofoglio LA; ICOA, University of Orléans, CNRS UMR 7311, Rue de Chartres, 45067 Orléans, France. Electronic address: .
Pokaż więcej
Źródło :
Drug discovery today [Drug Discov Today] 2022 Jul; Vol. 27 (7), pp. 1945-1953. Date of Electronic Publication: 2022 Feb 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Nucleosides*/analogs & derivatives
Nucleosides*/pharmacology
Humans ; RNA-Dependent RNA Polymerase/antagonists & inhibitors ; United States
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.
Autorzy :
de Amaral M; Comparative Metabolism and Endocrinology Laboratory, Department of Physiology, Federal University of Rio Grande do Sul (UFRGS), Sarmento Leite, 500, Porto Alegre, Rio Grande do Sul 90050-170, Brazil. Electronic address: .
Ienes-Lima J; Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States.
Pokaż więcej
Źródło :
Virus research [Virus Res] 2022 Jul 02; Vol. 315, pp. 198769. Date of Electronic Publication: 2022 Apr 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Anura*
Magainins*/chemistry
Magainins*/pharmacology
SARS-CoV-2*/drug effects
Animals ; COVID-19/drug therapy ; Humans
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents.
Autorzy :
Han J; College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.
Lee MK; Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.
Jang Y; Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.
Cho WJ; College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea. Electronic address: .
Kim M; Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea; Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło :
Drug discovery today [Drug Discov Today] 2022 Jul; Vol. 27 (7), pp. 1895-1912. Date of Electronic Publication: 2022 May 21.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
COVID-19*/drug therapy
Cyclophilin A/pharmacology ; Drug Repositioning ; Humans ; SARS-CoV-2 ; Virus Replication
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
A network biology approach to identify crucial host targets for COVID-19.
Autorzy :
Barman RK; Division of Virology, ICMR-National Institute of Cholera and Enteric Diseases, Kolkata 700010, India; Department of Computer Science and Engineering, Jadavpur University, Kolkata 700032, India.
Mukhopadhyay A; Department of Computer Science and Engineering, University of Kalyani, Kalyani 741235, West Bengal, India.
Maulik U; Department of Computer Science and Engineering, Jadavpur University, Kolkata 700032, India.
Das S; Division of Clinical Medicine, ICMR-National Institute of Cholera and Enteric Diseases, Kolkata 700010, India; ICMR-National Institute of Occupational Health, Ahmedabad 380016, India. Electronic address: .
Pokaż więcej
Źródło :
Methods (San Diego, Calif.) [Methods] 2022 Jul; Vol. 203, pp. 108-115. Date of Electronic Publication: 2022 Mar 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
COVID-19*/drug therapy
Autoantigens ; Cell Cycle Proteins ; Drug Repositioning ; Humans ; Nerve Tissue Proteins ; Pandemics ; SARS-CoV-2
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
SARS-CoV-2 couples evasion of inflammatory response to activated nucleotide synthesis.
Autorzy :
Qin C; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Rao Y; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Yuan H; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.; Department of Chemistry, Dornsife College of Arts, Letters and Sciences, University of Southern California, Los Angeles, CA 90089.
Wang TY; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Zhao J; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.; Florida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, FL 34987.
Espinosa B; Department of Chemistry, Dornsife College of Arts, Letters and Sciences, University of Southern California, Los Angeles, CA 90089.
Liu Y; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Zhang S; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Savas AC; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Liu Q; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Zarinfar M; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Rice S; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Henley J; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Comai L; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Graham NA; Mork Family Department of Chemical Engineering and Materials Science, Norris Comprehensive Cancer Center, Los Angeles, CA 90089.
Chen C; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Zhang C; Department of Chemistry, Dornsife College of Arts, Letters and Sciences, University of Southern California, Los Angeles, CA 90089.
Feng P; Section of Infection and Immunity, Herman Ostrow School of Dentistry, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2022 Jun 28; Vol. 119 (26), pp. e2122897119. Date of Electronic Publication: 2022 Jun 14.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Aspartate Carbamoyltransferase*/antagonists & inhibitors
COVID-19*/drug therapy
Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)*/antagonists & inhibitors
Dihydroorotase*/antagonists & inhibitors
Enzyme Inhibitors*/pharmacology
Enzyme Inhibitors*/therapeutic use
Pyrimidines*/antagonists & inhibitors
Pyrimidines*/biosynthesis
SARS-CoV-2*/drug effects
SARS-CoV-2*/physiology
Virus Replication*/drug effects
Animals ; Enzyme Activation/drug effects ; Humans ; Inflammation/drug therapy ; Mice ; RNA-Binding Proteins/metabolism ; Transcription Factor RelA/metabolism ; Viral Nonstructural Proteins/metabolism
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
New antivirals exploit viral feedback tricks for a cure without resistance.
Autorzy :
Balázsi G; Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794, USA; The Louis and Beatrice Laufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794, USA. Electronic address: .
Pokaż więcej
Źródło :
Cell [Cell] 2022 Jun 23; Vol. 185 (13), pp. 2210-2212.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Virus Diseases*/drug therapy
Feedback ; Humans
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Extracellular Polymeric Substances: Still Promising Antivirals.
Autorzy :
Bello-Morales R; Departamento de Biología Molecular, Edificio de Biología, Universidad Autónoma de Madrid, Darwin 2, Cantoblanco, 28049 Madrid, Spain.; Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Cantoblanco, 28049 Madrid, Spain.
Andreu S; Departamento de Biología Molecular, Edificio de Biología, Universidad Autónoma de Madrid, Darwin 2, Cantoblanco, 28049 Madrid, Spain.; Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Cantoblanco, 28049 Madrid, Spain.
Ruiz-Carpio V; Departamento de Biología Molecular, Edificio de Biología, Universidad Autónoma de Madrid, Darwin 2, Cantoblanco, 28049 Madrid, Spain.
Ripa I; Departamento de Biología Molecular, Edificio de Biología, Universidad Autónoma de Madrid, Darwin 2, Cantoblanco, 28049 Madrid, Spain.; Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Cantoblanco, 28049 Madrid, Spain.
López-Guerrero JA; Departamento de Biología Molecular, Edificio de Biología, Universidad Autónoma de Madrid, Darwin 2, Cantoblanco, 28049 Madrid, Spain.; Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Cantoblanco, 28049 Madrid, Spain.
Pokaż więcej
Źródło :
Viruses [Viruses] 2022 Jun 19; Vol. 14 (6). Date of Electronic Publication: 2022 Jun 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
HIV Infections*/drug therapy
Animals ; Extracellular Polymeric Substance Matrix ; Polysaccharides/pharmacology
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
[The antiviral targeting potential of viroporins].
Autorzy :
Sund JD; Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.; Biomedicinsk Institut, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
Bollerup S; Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.
Glamann JB; Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.
Vinten CA; Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.
Jensen LR; Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.
Toft-Bethelsen TL; Institut for Neurovidenskab, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
Bentzen BH; Biomedicinsk Institut, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
Kledal TN; Synklino.; Dansk Selskab for Geriatri.
Weis N; Infektionsmedicinsk Afdeling, Københavns Universitetshospital - Hvidovre Hospital.; Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
Rosenkilde M; Biomedicinsk Institut, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet.; Synklino.
Pokaż więcej
Źródło :
Ugeskrift for laeger [Ugeskr Laeger] 2022 Jun 13; Vol. 184 (24).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
COVID-19*/drug therapy
Amantadine ; Humans ; SARS-CoV-2 ; Viroporin Proteins
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
A database of anti-coronavirus peptides.
Autorzy :
Zhang Q; Medical College, Guizhou University, Guiyang, 550025, China.
Chen X; Medical College, Guizhou University, Guiyang, 550025, China.
Li B; Medical College, Guizhou University, Guiyang, 550025, China.
Lu C; Medical College, Guizhou University, Guiyang, 550025, China.
Yang S; Medical College, Guizhou University, Guiyang, 550025, China.
Long J; Medical College, Guizhou University, Guiyang, 550025, China.
Chen H; Medical College, Guizhou University, Guiyang, 550025, China. .
Huang J; School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 611731, China. .
He B; Medical College, Guizhou University, Guiyang, 550025, China. .
Pokaż więcej
Źródło :
Scientific data [Sci Data] 2022 Jun 13; Vol. 9 (1), pp. 294. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji :
Dataset; Journal Article
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
COVID-19*/drug therapy
SARS-CoV-2*/drug effects
Databases, Chemical ; Humans ; Peptides/chemistry ; Peptides/pharmacology ; Peptides/therapeutic use
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Autorzy :
Levin MJ; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Ustianowski A; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
De Wit S; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Launay O; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Avila M; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Templeton A; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Yuan Y; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Seegobin S; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Ellery A; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Levinson DJ; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Ambery P; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Arends RH; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Beavon R; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Dey K; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Garbes P; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Kelly EJ; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Koh GCKW; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Near KA; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Padilla KW; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Psachoulia K; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Sharbaugh A; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Streicher K; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Pangalos MN; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Esser MT; From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) - all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de Paris, INSERM French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, Assistance Publique-Hôpitaux de Paris, Paris (O.L.); Chicago Clinical Research Institute, Chicago (D.J.L.); Clinical Development, Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (P.A.); Clinical Pharmacology and Quantitative Pharmacology (R.H.A.), Clinical Development (K.D., P.G., K.A.N., K.P.), Biometrics (M.A., Y.Y.), Translational Medicine (E.J.K., K.S.), and Vaccines and Immune Therapies (M.T.E.), Biopharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD; and Clinical Development, Vaccines and Immune Therapies, Biopharmaceuticals Research and Development, AstraZeneca, Durham, NC (K.W.P., A.S.).
Pokaż więcej
Corporate Authors :
PROVENT Study Group
Źródło :
The New England journal of medicine [N Engl J Med] 2022 Jun 09; Vol. 386 (23), pp. 2188-2200. Date of Electronic Publication: 2022 Apr 20.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antiviral Agents*/administration & dosage
Antiviral Agents*/therapeutic use
COVID-19*/prevention & control
Adult ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing/administration & dosage ; Antibodies, Neutralizing/therapeutic use ; Double-Blind Method ; Drug Combinations ; Humans ; Injections, Intramuscular ; SARS-CoV-2
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
A multilevel approach for screening natural compounds as an antiviral agent for COVID-19.
Autorzy :
Vasighi M; Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences (IASBS), 45137-66731 Zanjan, Iran. Electronic address: .
Romanova J; Department of Inorganic Chemistry, Sofia University 'St. Kl. Ohridski', Sofia, Bulgaria. Electronic address: .
Nedyalkova M; Department of Inorganic Chemistry, Sofia University 'St. Kl. Ohridski', Sofia, Bulgaria; Chemistry Department, University of Fribourg, Fribourg, Switzerland. Electronic address: .
Pokaż więcej
Źródło :
Computational biology and chemistry [Comput Biol Chem] 2022 Jun; Vol. 98, pp. 107694. Date of Electronic Publication: 2022 May 11.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
COVID-19*/drug therapy
Biological Products/chemistry ; Biological Products/pharmacology ; Drug Evaluation, Preclinical ; Humans ; Ligands ; Molecular Docking Simulation ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/metabolism
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins.
Autorzy :
Yan Y; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Yang J; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China; School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China.
Xiao D; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Yin J; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Song M; Beijing Institute of Basic Medical Sciences, Beijing, 100850, China.
Xu Y; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Zhao L; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Dai Q; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Li Y; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Wang C; Beijing Institute of Basic Medical Sciences, Beijing, 100850, China.
Wang Z; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China; Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, China.
Ren X; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Yang X; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Ni J; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Liu M; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Guo X; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Li W; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Chen X; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China; Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, China.
Liu Z; Beijing Institute of Basic Medical Sciences, Beijing, 100850, China.
Cao R; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: .
Zhong W; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: .
Pokaż więcej
Źródło :
Antiviral research [Antiviral Res] 2022 Jun; Vol. 202, pp. 105325. Date of Electronic Publication: 2022 Apr 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Benzamidines*/chemistry
Benzamidines*/pharmacology
Flavivirus*/drug effects
Guanidines*/chemistry
Guanidines*/pharmacology
Zika Virus*/drug effects
Animals ; Haplorhini ; Humans ; Mice ; Molecular Docking Simulation ; Viral Envelope Proteins/metabolism
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Depicting the inhibitory potential of polyphenols from Isatis indigotica root against the main protease of SARS CoV-2 using computational approaches.
Autorzy :
Ghosh R; School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Bhubaneswar, India.
Chakraborty A; School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Bhubaneswar, India.
Biswas A; School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Bhubaneswar, India.
Chowdhuri S; School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Bhubaneswar, India.
Pokaż więcej
Źródło :
Journal of biomolecular structure & dynamics [J Biomol Struct Dyn] 2022 Jun; Vol. 40 (9), pp. 4110-4121. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Coronavirus 3C Proteases*/antagonists & inhibitors
Isatis*/chemistry
Protease Inhibitors*/chemistry
Protease Inhibitors*/pharmacology
SARS-CoV-2*/drug effects
COVID-19/drug therapy ; Humans ; Lopinavir ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Polyphenols/pharmacology
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Systematic optimization of host-directed therapeutic targets and preclinical validation of repositioned antiviral drugs.
Autorzy :
Xie D; Beijing Institute of Radiation Medicine, Beijing, China, 100850.
He S; Beijing Institute of Radiation Medicine, Beijing, China, 100850.
Han L; Beijing Institute of Pharmacology and Toxicology, Beijing, China, 100850.
Wu L; Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China, 300072.
Huang H; Department of Biological Medicines, School of Pharmacy, Fudan University, Shanghai, China, 201203.
Tao H; Beijing Institute of Radiation Medicine, Beijing, China, 100850.
Zhou P; Beijing Institute of Radiation Medicine, Beijing, China, 100850.
Shi X; Department of Biological Medicines, School of Pharmacy, Fudan University, Shanghai, China, 201203.
Bai H; BioMap (Beijing) Intelligence Technology Limited, Beijing, China, 100005.
Bo X; Beijing Institute of Radiation Medicine, Beijing, China, 100850.
Pokaż więcej
Źródło :
Briefings in bioinformatics [Brief Bioinform] 2022 May 13; Vol. 23 (3).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Influenza A virus*/genetics
Dextromethorphan ; Humans
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
The Oligomeric Assemblies of Cytomegalovirus Core Nuclear Egress Proteins Are Associated with Host Kinases and Show Sensitivity to Antiviral Kinase Inhibitors.
Autorzy :
Kicuntod J; Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Häge S; Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Hahn F; Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Sticht H; Bioinformatics, Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Marschall M; Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Pokaż więcej
Źródło :
Viruses [Viruses] 2022 May 11; Vol. 14 (5). Date of Electronic Publication: 2022 May 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents*/metabolism
Antiviral Agents*/pharmacology
Cytomegalovirus*/metabolism
Humans ; Infant, Newborn ; Viral Proteins/metabolism ; Virus Release ; Virus Replication
Czasopismo naukowe
Szczegóły Pełny tekst Pełny tekst
Podgląd okładki
Tytuł :
Guanine quadruplexes in the RNA genome of the tick-borne encephalitis virus: their role as a new antiviral target and in virus biology.
Autorzy :
Holoubek J; Veterinary Research Institute, Emerging Viral Diseases, Brno CZ-62100, Czech Republic.; Department of Experimental Biology, Faculty of Science, Masaryk University, CZ-62500 Brno, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-37005 Ceske Budejovice, Czech Republic.
Bednářová K; Department of Biophysics of Nucleic Acids, Institute of Biophysics of the Czech Academy of Sciences, Brno CZ-61200, Czech Republic.
Haviernik J; Veterinary Research Institute, Emerging Viral Diseases, Brno CZ-62100, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-37005 Ceske Budejovice, Czech Republic.
Huvarová I; Veterinary Research Institute, Emerging Viral Diseases, Brno CZ-62100, Czech Republic.
Dvořáková Z; Department of Biophysics of Nucleic Acids, Institute of Biophysics of the Czech Academy of Sciences, Brno CZ-61200, Czech Republic.
Černý J; Faculty of Tropical Agrisciences, Czech University of Life Sciences Prague, CZ-16500 Prague, Czech Republic.
Outlá M; Department of Biophysical Chemistry and Molecular Oncology, Institute of Biophysics of the Czech Academy of Sciences, Brno CZ-61200, Czech Republic.; National Centre for Biomolecular Research, Faculty of Science, Masaryk University, CZ-62500 Brno, Czech Republic.
Salát J; Veterinary Research Institute, Emerging Viral Diseases, Brno CZ-62100, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-37005 Ceske Budejovice, Czech Republic.
Konkol'ová E; Institute of Organic Chemistry and Biochemistry of the Czech Academy ofSciences, CZ-16000 Prague, Czech Republic.
Boura E; Institute of Organic Chemistry and Biochemistry of the Czech Academy ofSciences, CZ-16000 Prague, Czech Republic.
Růžek D; Veterinary Research Institute, Emerging Viral Diseases, Brno CZ-62100, Czech Republic.; Department of Experimental Biology, Faculty of Science, Masaryk University, CZ-62500 Brno, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-37005 Ceske Budejovice, Czech Republic.
Vorlíčková M; Department of Biophysics of Nucleic Acids, Institute of Biophysics of the Czech Academy of Sciences, Brno CZ-61200, Czech Republic.
Eyer L; Veterinary Research Institute, Emerging Viral Diseases, Brno CZ-62100, Czech Republic.; Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, CZ-37005 Ceske Budejovice, Czech Republic.
Renčiuk D; Department of Biophysics of Nucleic Acids, Institute of Biophysics of the Czech Academy of Sciences, Brno CZ-61200, Czech Republic.
Pokaż więcej
Źródło :
Nucleic acids research [Nucleic Acids Res] 2022 May 06; Vol. 50 (8), pp. 4574-4600.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Encephalitis Viruses, Tick-Borne*/drug effects
Encephalitis Viruses, Tick-Borne*/genetics
G-Quadruplexes*
Encephalitis, Tick-Borne/drug therapy ; Encephalitis, Tick-Borne/genetics ; Humans ; Ligands ; RNA, Viral/genetics ; RNA-Dependent RNA Polymerase/genetics
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
A systematic approach to identify host targets and rapidly deliver broad-spectrum antivirals.
Autorzy :
Olivet J; Structural Biology Unit, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research and Department of Microbiology, Immunology and Transplantation, Catholic University of Leuven (KU Leuven), Leuven, Belgium; Laboratory of Viral Interactomes Networks, Unit of Molecular Biology of Diseases, Interdisciplinary Cluster for Applied Genoproteomics (GIGA Institute), University of Liège, Liège, Belgium.
Maseko SB; Laboratory of Viral Interactomes Networks, Unit of Molecular Biology of Diseases, Interdisciplinary Cluster for Applied Genoproteomics (GIGA Institute), University of Liège, Liège, Belgium.
Volkov AN; VIB-VUB Center for Structural Biology, Flemish Institute of Biotechnology (VIB), Brussels, Belgium; Jean Jeener NMR Centre, Free University of Brussels (VUB), Brussels, Belgium.
Salehi-Ashtiani K; Division of Science and Math, New York University Abu Dhabi, Abu Dhabi, UAE.
Das K; Structural Biology Unit, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research and Department of Microbiology, Immunology and Transplantation, Catholic University of Leuven (KU Leuven), Leuven, Belgium.
Calderwood MA; Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute (DFCI), Boston, MA, USA; Department of Genetics, Blavatnik Institute, Harvard Medical School (HMS), Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Twizere JC; Laboratory of Viral Interactomes Networks, Unit of Molecular Biology of Diseases, Interdisciplinary Cluster for Applied Genoproteomics (GIGA Institute), University of Liège, Liège, Belgium; Division of Science and Math, New York University Abu Dhabi, Abu Dhabi, UAE; TERRA Research and Teaching Centre, Microbial Processes and Interactions (MiPI), Gembloux Agro Bio-tech, University of Liège, Gembloux, Belgium. Electronic address: .
Gorgulla C; Department of Cancer Biology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School (HMS), Boston, MA, USA; Department of Physics, Faculty of Arts and Sciences, Harvard University, Cambridge, MA, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2022 May 04; Vol. 30 (5), pp. 1797-1800. Date of Electronic Publication: 2022 Feb 28.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Virus Internalization*
Host-Pathogen Interactions
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Investigational New Drug Enabling Nonclinical Safety Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent.
Autorzy :
Shearer J; 61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Wolfe G; Gary Wolfe Toxicology, LLC, Herndon, VA, USA.
Sampath A; 61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.; Dynavax Technologies Corporation, Emeryville, CA, USA.
Warfield KL; 61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.
Kaufman B; 61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.; OncoC4, Rockville, MD, USA.
Ramstedt U; 61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.; AbViro, Bethesda, MD, USA.
Treston A; 61424Emergent BioSolutions Inc, Gaithersburg, MD, USA.; Treadwell Therapeutics, Toronto, Canada.
Pokaż więcej
Źródło :
International journal of toxicology [Int J Toxicol] 2022 May-Jun; Vol. 41 (3), pp. 182-200. Date of Electronic Publication: 2022 Apr 15.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/therapeutic use
Antiviral Agents*/toxicity
Drugs, Investigational*/toxicity
Administration, Oral ; Animals ; Dogs ; Maximum Tolerated Dose ; Mice ; Rats
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Fractionation of sulfated galactan from the red alga Botryocladia occidentalis separates its anticoagulant and anti-SARS-CoV-2 properties.
Autorzy :
Kim SB; Department of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA.
Zoepfl M; Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia, USA.
Samanta P; Department of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA.
Zhang F; Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, USA.
Xia K; Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, USA.
Thara R; Department of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA.
Linhardt RJ; Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, USA.
Doerksen RJ; Department of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA; Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, Oxford, Mississippi, USA.
McVoy MA; Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia, USA.
Pomin VH; Department of BioMolecular Sciences, University of Mississippi, University, Mississippi, USA; Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, Oxford, Mississippi, USA. Electronic address: .
Pokaż więcej
Źródło :
The Journal of biological chemistry [J Biol Chem] 2022 May; Vol. 298 (5), pp. 101856. Date of Electronic Publication: 2022 Mar 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Anticoagulants*/chemistry
Anticoagulants*/pharmacology
Antiviral Agents*/chemistry
Antiviral Agents*/pharmacology
Galactans*/chemistry
Galactans*/pharmacology
Rhodophyta*/chemistry
SARS-CoV-2*/drug effects
COVID-19 ; HEK293 Cells ; Humans ; Spike Glycoprotein, Coronavirus/chemistry ; Sulfates/chemistry
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 167239

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies